|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: LASP1 |
Gene summary for LASP1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | LASP1 | Gene ID | 3927 |
| Gene name | LIM and SH3 protein 1 | |
| Gene Alias | Lasp-1 | |
| Cytomap | 17q12 | |
| Gene Type | protein-coding | GO ID | GO:0006810 | UniProtAcc | B4DIC4 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 3927 | LASP1 | P79T-E | Human | Esophagus | ESCC | 2.69e-26 | 3.01e-01 | 0.1154 |
| 3927 | LASP1 | P80T-E | Human | Esophagus | ESCC | 3.12e-18 | 6.17e-01 | 0.155 |
| 3927 | LASP1 | P82T-E | Human | Esophagus | ESCC | 3.01e-11 | 7.13e-01 | 0.1072 |
| 3927 | LASP1 | P83T-E | Human | Esophagus | ESCC | 2.05e-18 | 4.35e-01 | 0.1738 |
| 3927 | LASP1 | P84T-E | Human | Esophagus | ESCC | 2.53e-14 | 1.47e+00 | 0.0933 |
| 3927 | LASP1 | P89T-E | Human | Esophagus | ESCC | 1.88e-14 | 7.47e-01 | 0.1752 |
| 3927 | LASP1 | P91T-E | Human | Esophagus | ESCC | 6.71e-05 | 7.47e-01 | 0.1828 |
| 3927 | LASP1 | P94T-E | Human | Esophagus | ESCC | 1.88e-03 | 8.11e-01 | 0.0879 |
| 3927 | LASP1 | P104T-E | Human | Esophagus | ESCC | 1.85e-07 | 5.70e-01 | 0.0931 |
| 3927 | LASP1 | P107T-E | Human | Esophagus | ESCC | 9.51e-16 | 3.63e-01 | 0.171 |
| 3927 | LASP1 | P126T-E | Human | Esophagus | ESCC | 9.24e-06 | 1.29e+00 | 0.1125 |
| 3927 | LASP1 | P127T-E | Human | Esophagus | ESCC | 1.04e-16 | 1.64e-01 | 0.0826 |
| 3927 | LASP1 | P128T-E | Human | Esophagus | ESCC | 1.89e-43 | 1.54e+00 | 0.1241 |
| 3927 | LASP1 | P130T-E | Human | Esophagus | ESCC | 1.03e-43 | 9.04e-01 | 0.1676 |
| 3927 | LASP1 | S43 | Human | Liver | Cirrhotic | 3.96e-05 | -5.42e-02 | -0.0187 |
| 3927 | LASP1 | HCC1_Meng | Human | Liver | HCC | 1.73e-63 | 2.02e-02 | 0.0246 |
| 3927 | LASP1 | HCC2_Meng | Human | Liver | HCC | 1.69e-36 | 1.60e-01 | 0.0107 |
| 3927 | LASP1 | cirrhotic2 | Human | Liver | Cirrhotic | 8.33e-08 | 1.71e-01 | 0.0201 |
| 3927 | LASP1 | cirrhotic3 | Human | Liver | Cirrhotic | 5.78e-03 | 1.35e-01 | 0.0215 |
| 3927 | LASP1 | HCC1 | Human | Liver | HCC | 2.81e-15 | 4.49e+00 | 0.5336 |
| Page: 1 2 3 4 5 6 7 8 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Breast |  | IDC: Invasive ductal carcinoma |
| DCIS: Ductal carcinoma in situ | ||
| Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| GC |  | CAG: Chronic atrophic gastritis |
| CAG with IM: Chronic atrophic gastritis with intestinal metaplasia | ||
| CSG: Chronic superficial gastritis | ||
| GC: Gastric cancer | ||
| SIM: Severe intestinal metaplasia | ||
| WIM: Wild intestinal metaplasia | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:004206010 | Cervix | CC | wound healing | 109/2311 | 422/18723 | 1.84e-14 | 1.57e-11 | 109 |
| GO:001081010 | Cervix | CC | regulation of cell-substrate adhesion | 69/2311 | 221/18723 | 8.57e-14 | 5.69e-11 | 69 |
| GO:00315898 | Cervix | CC | cell-substrate adhesion | 96/2311 | 363/18723 | 1.48e-13 | 8.85e-11 | 96 |
| GO:000701510 | Cervix | CC | actin filament organization | 109/2311 | 442/18723 | 4.92e-13 | 2.45e-10 | 109 |
| GO:009013210 | Cervix | CC | epithelium migration | 90/2311 | 360/18723 | 2.45e-11 | 6.11e-09 | 90 |
| GO:00016679 | Cervix | CC | ameboidal-type cell migration | 110/2311 | 475/18723 | 2.66e-11 | 6.36e-09 | 110 |
| GO:001063110 | Cervix | CC | epithelial cell migration | 89/2311 | 357/18723 | 3.72e-11 | 8.54e-09 | 89 |
| GO:003297010 | Cervix | CC | regulation of actin filament-based process | 96/2311 | 397/18723 | 4.00e-11 | 8.54e-09 | 96 |
| GO:00071639 | Cervix | CC | establishment or maintenance of cell polarity | 63/2311 | 218/18723 | 4.25e-11 | 8.76e-09 | 63 |
| GO:009013010 | Cervix | CC | tissue migration | 90/2311 | 365/18723 | 5.42e-11 | 1.05e-08 | 90 |
| GO:190290310 | Cervix | CC | regulation of supramolecular fiber organization | 92/2311 | 383/18723 | 1.49e-10 | 2.48e-08 | 92 |
| GO:01501159 | Cervix | CC | cell-substrate junction organization | 37/2311 | 101/18723 | 3.20e-10 | 4.46e-08 | 37 |
| GO:003295610 | Cervix | CC | regulation of actin cytoskeleton organization | 86/2311 | 358/18723 | 5.90e-10 | 7.51e-08 | 86 |
| GO:004325410 | Cervix | CC | regulation of protein-containing complex assembly | 96/2311 | 428/18723 | 2.91e-09 | 3.05e-07 | 96 |
| GO:00070448 | Cervix | CC | cell-substrate junction assembly | 34/2311 | 95/18723 | 3.35e-09 | 3.45e-07 | 34 |
| GO:001063210 | Cervix | CC | regulation of epithelial cell migration | 72/2311 | 292/18723 | 4.52e-09 | 4.43e-07 | 72 |
| GO:00019528 | Cervix | CC | regulation of cell-matrix adhesion | 40/2311 | 128/18723 | 1.32e-08 | 1.04e-06 | 40 |
| GO:00071608 | Cervix | CC | cell-matrix adhesion | 60/2311 | 233/18723 | 1.58e-08 | 1.23e-06 | 60 |
| GO:011005310 | Cervix | CC | regulation of actin filament organization | 67/2311 | 278/18723 | 4.01e-08 | 2.54e-06 | 67 |
| GO:00300108 | Cervix | CC | establishment of cell polarity | 42/2311 | 143/18723 | 4.30e-08 | 2.62e-06 | 42 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| LASP1 | SNV | Missense_Mutation | novel | c.108N>T | p.Lys36Asn | p.K36N | Q14847 | protein_coding | tolerated(0.05) | benign(0.033) | TCGA-AN-A0FS-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| LASP1 | SNV | Missense_Mutation | c.650N>C | p.Asp217Ala | p.D217A | Q14847 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-BH-A0DH-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD | |
| LASP1 | SNV | Missense_Mutation | c.326N>A | p.Arg109Lys | p.R109K | Q14847 | protein_coding | deleterious(0.01) | probably_damaging(0.964) | TCGA-BH-A18P-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD | |
| LASP1 | insertion | In_Frame_Ins | novel | c.233_234insAATACTATTCCTATT | p.Ser78delinsArgIleLeuPheLeuPhe | p.S78delinsRILFLF | Q14847 | protein_coding | TCGA-A2-A0D2-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | ||
| LASP1 | insertion | In_Frame_Ins | novel | c.235_236insCAGATA | p.Glu79delinsAlaAspLys | p.E79delinsADK | Q14847 | protein_coding | TCGA-A2-A0D2-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | ||
| LASP1 | SNV | Missense_Mutation | c.90C>G | p.Phe30Leu | p.F30L | Q14847 | protein_coding | deleterious(0) | benign(0.442) | TCGA-IR-A3LI-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| LASP1 | SNV | Missense_Mutation | c.164C>T | p.Ala55Val | p.A55V | Q14847 | protein_coding | tolerated(0.06) | benign(0.051) | TCGA-AA-3949-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
| LASP1 | SNV | Missense_Mutation | c.164N>T | p.Ala55Val | p.A55V | Q14847 | protein_coding | tolerated(0.06) | benign(0.051) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| LASP1 | SNV | Missense_Mutation | novel | c.64N>A | p.Asp22Asn | p.D22N | Q14847 | protein_coding | deleterious(0) | possibly_damaging(0.866) | TCGA-A5-A2K5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| LASP1 | SNV | Missense_Mutation | c.616N>T | p.Arg206Trp | p.R206W | Q14847 | protein_coding | deleterious(0.01) | probably_damaging(0.965) | TCGA-AP-A051-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |